Breast Cancer Clinical Trial
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT. Aerobic exercise has been demonstrated to improve patient quality of life, cardiac outcomes, and cardiorespiratory fitness in patients with cancer receiving cardiotoxic systemic therapies, but the effects of aerobic exercise on patients at high risk for radiation induced heart disease (RIHD) is unknown. In addition, home-based cardiac rehabilitation has not been tested in patients with thoracic cancers.
Pathologically confirmed or radiographically diagnosed non-small cell lung cancer, small cell lung cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, sarcoma, thymoma, or left-sided breast cancer.
Planning to receive neo-adjuvant, adjuvant, or definitive radiation therapy to the thorax with curative intent.
Willing to participate in home-based cardiac rehabilitation program and be monitored remotely via smart phone application
Possess a smart phone or tablet capable of supporting teleHeart application
Willing and eligible to co-enroll in the Cardiovascular Toxicity in Cancer and Improvement in Recovery (SURVIVE) Registry Study (HRPO# 201801031).
At least 18 years of age.
ECOG performance status ≤ 2
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Presence of distant metastatic disease (except patients with lymphoma).
Life expectancy less than 6 months
Patient lives in skilled nursing facility, chronic care facility, nursing home, or palliative care or hospice facility
Unable to walk
Presence of significant cancer disease burden that would make patient unlikely to tolerate cardiac rehabilitation (CR)
Diagnosis of primary cervical esophageal cancer.
Presence of unstable angina.
Recipient of heart transplant.
Patient on cardiac transplant list or has a ventricular assist device
Patient's baseline weight > 300 lbs (due to weight limitations of the scale and bioelectrical impedance device)
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Other medical comorbidities that make the patient unable to participate in the CR program or other assessments involved with this study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Saint Louis Missouri, 63110, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.